Table 1.

ASCVD risk in 4 categorized of the study population.

ASCVD risk	Low		Borderline			Intermediate			High
	<5%		5%–7.4%			7.5%–19.9%			≥20%
	Mean ± SD	95% CI	Mean ± SD	95% CI	P value	Mean ± SD	95% CI	P value	Mean ± SD	95% CI	P value
Anthropometric measurements
Subjects, n (%)	2449 (50.2%)		641 (13.1%)			1404 (28.8%)			387 (7.9%)
Age (yr)	49.5 ± 6.2	49.2–49.7	55 ± 6.6	54.5–55.5	<.001	59.6 ± 7	59.2–60	<.001	68 ± 6.1	67.4–68.7	<.001
Gender, male	1104 (45.1%)		483 (75.4%)			1167 (83.1%)			337 (87.1%)
Smoking (%)	123 (5%)		126 (19.7%)			433 (30.8%)			102 (26.4%)
Body mass index (kg/m2)	24 ± 3.6	23.8–24.1	25.2 ± 3.3	24.9–25.4	<.001	25.2 ± 3.2	25–25.4	<.001	25.6 ± 3.2	25.3–26	<.001
Systolic blood pressure (mm Hg)	121.9 ± 15.9	121.2–122.5	129.3 ± 17.1	128–130.7	<.001	134.4 ± 16.8	133.5–135.2	<.001	144.4 ± 15.9	142.9–146	<.001
Diastolic blood pressure (mm Hg)	74.5 ± 11.2	74.1–75	79.8 ± 11.1	78.9–80.7	<.001	81.3 ± 10.8	80.8–81.9	<.001	83.4 ± 10.7	82.3–84.5	<.001
Biochemical parameters
Neutrophil-to-lymphocyte ratio	1.93 ± 0.77	1.9–1.96	1.88 ± 0.78	1.82–1.94	.47	1.95 ± 0.77	1.91–1.99	.90	2.1 ± 0.89	2–2.18	<.001
Monocyte-to-lymphocyte ratio	0.24 ± 0.09	0.23–0.24	0.24 ± 0.1	0.24–0.25	.22	0.25 ± 0.09	0.25–0.26	<.001	0.27 ± 0.1	0.25–0.28	<.001
Platelet-to-lymphocyte ratio	149 ± 53.9	146.8–151.1	144.2 ± 54.4	139.9–148.4	.20	142.2 ± 54.6	139.4–145.1	.001	153.8 ± 66.8	147.1–160.5	.38
Cholesterol (mg/dL)	202.6 ± 35.8	201.2–204	203 ± 36.3	200.2–205.9	.99	204.9 ± 37.1	203–206.9	.23	201 ± 38.2	197.1–204.9	.86
Triglycerides (mg/dL)	112.3 ± 65.4	109.8–114.9	142 ± 83.2	135.5–148.4	<.001	148.6 ± 89.5	143.9–153.3	<.001	149 ± 88.9	140–157.9	<.001
HDL (mg/dL)	56.5 ± 14.9	55.9–57	49.1 ± 12.6	48.2–50.1	<.001	47.4 ± 12.6	46.7–48	<.001	45.8 ± 11.8	44.6–47	<.001
LDL (mg/dL)	127.3 ± 32.1	126.1–128.6	131.4 ± 34	128.7–134	.03	132 ± 33.9	130.2–133.7	<.001	129.6 ± 35.6	126–133.3	.60
Fasting glucose (mg/dL)	96.5 ± 14.9	95.9–97	102.5 ± 19.4	101–104	<.001	104.8 ± 22.4	103.6–106	<.001	113.7 ± 29.4	110.8–116.7	<.001
HbA1c (%)	5.5 ± 0.5	5.4–5.5	5.7 ± 0.76	5.7–5.8	<.001	5.9 ± 0.9	5.8–5.9	<.001	6.3 ± 1	6.2–6.4	<.001
Creatinine (mg/dL)	0.81 ± 0.2	0.8–0.82	0.90 ± 0.19	0.88–0.91	<.001	0.94 ± 0.2	0.93–0.95	<.001	1 ± 0.29	0.97–1.03	<.001
Urine protein	0.09 ± 0.26	0.08–0.10	0.13 ± 0.37	0.11–0.16	<.001	0.16 ± 0.42	0.14–0.18	<.001	0.28 ± 0.60	0.22–0.34	<.001
baPWV and ABI measurements
RbaPWV (cm/s)	1340 ± 218	1331–1348	1467 ± 314	1446–1488	<.001	1567 ± 314	1551–1584	<.001	1811 ± 387	1772–1849	<.001
LbaPWV (cm/s)	1351 ± 224	1342–1360	1474 ± 266	1453–1494	<.001	1580 ± 319	1563–1597	<.001	1831 ± 401	1790–1871	<.001
RABI	1.14 ± 0.08	1.13–1.14	1.15 ± 0.08	1.15–1.16	<.001	1.16 ± 0.08	1.15–1.16	<.001	1.16 ± 0.08	1.15–1.17	<.001
LABI	1.14 ± 0.08	1.13–1.14	1.16 ± 0.08	1.15–1.16	<.001	1.16 ± 0.08	1.15–1.16	<.001	1.17 ± 0.08	1.16–1.17	<.001
Risk assessment indicators
MS	1.5 ± 1.1	1.4–1.6	2 ± 1.2	1.9–2.1	<.001	2.3 ± 1.2	2.2–2.3	<.001	2.7 ± 1.2	2.6–2.9	<.001
FRS	2.5 ± 2.1	2.4–2.6	6.8 ± 3.3	6.5–7	<.001	11.5 ± 5.4	11.2–11.8	<.001	16.3 ± 6.1	15.7–17	<.001
eGFR (mL/min/1.73 m2)	90.6 ± 19.5	89.8–91.3	85.9 ± 17.6	84.5–87.3	<.001	82 ± 17.7	81–82.9	<.001	76.3 ± 17.9	74.5–78.1	<.001
Carotid plaque (%)	576 (23.5%)		227 (35.4%)			650 (46.3%)			238 (61.5%)
Age (yr)	49.5 ± 6.2	49.2–49.7	55 ± 6.6	54.5–55.5	<.001	59.6 ± 7	59.2–60	<.001	68 ± 6.1	67.4–68.7	<.001
Vascular age (yr)	54.9 ± 11	54.5–55.3	62.3 ± 12.9	61.3–63.3	<.001	68.3 ± 14.9	67.5–69.1	<.001	81.2 ± 18.2	80–83.7	<.001
Vascular age – age (yr)	5.4 ± 9.1	5.1–5.8	7.2 ± 11.1	6.4–8.1	.002	8.8 ± 13.3	8.1–9.4	<.001	14 ± 17.3	12.3–15.8	<.001
Hazard ratio	1.11 ± 0.19	1.11–1.12	1.13 ± 0.21	1.12–1-15	.07	1.15 ± 0.23	1.14–1.16	<.001	1.21 ± 0.26	1.18–1.24	<.001
Carotid plaque (%)	576 (23.5%)		227 (35.4%)			650 (46.3%)			238 (61.5%)